Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study

Roger B. Cohen,Jean-Pierre Delord,Toshihiko Doi,Sarina Anne Piha-Paul,Stephen V. Liu,Jill Gilbert,Alain Patrick Algazi,Silvia Damian,Ruey-Long Hong,Christophe Le Tourneau,Daphne Day,Andrea Varga,Elena Élez,John M. Wallmark,Sanatan Saraf,Pradeep Thanigaimani,Jonathan D. Cheng,Bhumsuk Keam

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study

2018

Roger B. Cohen
Jean-Pierre Delord
Toshihiko Doi
Sarina Anne Piha-Paul
Stephen V. Liu
Jill Gilbert
Alain Patrick Algazi
Silvia Damian
Ruey-Long Hong
Christophe Le Tourneau
Daphne Day
Andrea Varga
Elena Élez
John M. Wallmark
Sanatan Saraf
Pradeep Thanigaimani
Jonathan D. Cheng
Bhumsuk Keam

Objectives: Treatment options for patients with unresectable or metastatic salivary gland carcinoma (SGC) are limited. Safety and efficacy of pembrolizumab for SGC expressing programmed death ligand 1 (PD-L1) were explored.

Keywords:

Pathology
Salivary gland carcinoma
Oncology
Pembrolizumab
Internal medicine
Medicine
Interstitial lung disease
Clinical endpoint
Salivary gland cancer
Adverse effect
Discontinuation
General surgery
Cohort
Response Evaluation Criteria in Solid Tumors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations